Almonertinib vs Rezivertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Almonertinib

Marketed by Hansoh Pharmaceutical Group and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04500717 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT04841811 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.): ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). (met)

Result source: NCT04500717

Rezivertinib

Marketed by Beta Pharma, Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Reliable signal

NCT03866499 · Phase 3 · status unknown

This trial randomized 369 patients to BPI-7711 or active-controlled gefitinib with full blinding of participants, care providers, investigators, and outcome assessors, testing a hard clinical endpoint (progression-free survival) that is standard for regulatory approval in NSCLC. The primary comparison was statistically significant and favored BPI-7711, with a nearly doubled median PFS and a strong hazard ratio, supporting confidence in the result.

Next expected readout: December 2030 · NCT06955325 (registry estimate)

Reported efficacy

Progression-free survival (up to approximately 16 months): REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 (met)

Result source: NCT03866499

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlmonertinibRezivertinib
PFS, median—Trial running · NCT06417008—Trial running · NCT06955325
OS, median—Trial running · NCT06417008—Trial running · NCT06955325
ORR—Trial running · NCT06417008—Trial running · NCT06955325
Duration of response, median—Trial running · NCT06417008—Trial running · NCT06955325

PFS, median

Almonertinib
—Trial running · NCT06417008
Rezivertinib
—Trial running · NCT06955325

OS, median

Almonertinib
—Trial running · NCT06417008
Rezivertinib
—Trial running · NCT06955325

ORR

Almonertinib
—Trial running · NCT06417008
Rezivertinib
—Trial running · NCT06955325

Duration of response, median

Almonertinib
—Trial running · NCT06417008
Rezivertinib
—Trial running · NCT06955325
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Almonertinib
ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). NCT04500717 · Phase 3 · design grade: moderate · publication or press release
Rezivertinib
REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 NCT03866499 · Phase 3 · design grade: strong · publication or press release
ORR by blinded independent central review 64.6% (95% CI 58.0%-70.8%) NCT03812809 · Phase 2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almonertinib's landscape · Rezivertinib's landscape